SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CEPH -- Ignore unavailable to you. Want to Upgrade?

To: Kevin G. O'Neill who wrote (655)4/14/1998 3:06:00 PM
From: Tom Todd  Respond to of 998
 
Eerily quiet here on this thread. Does anyone have a clue as to when the other shoe may drop? Days? Weeks? Months?

-tt



To: Kevin G. O'Neill who wrote (655)4/15/1998 8:02:00 AM
From: DOLLAR BILL  Respond to of 998
 
Are the odds of myotrophin getting FDA approval by May 11th fairly good at this point? How much would approval move this stock?



To: Kevin G. O'Neill who wrote (655)4/21/1998 9:12:00 AM
From: Kevin G. O'Neill  Read Replies (1) | Respond to of 998
 
FYI: Cephalon coverage in the Wall Street Journal; pretty negative.

interactive.wsj.com!&time=04/21+02:10

Sounds like others have a better approach to the science of the neuroimmunophilins. (I've been out of this one for a while but still keep an eye on it.) -kgo


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News